How India Exports Irinotecan to the World

Irinotecan has been a pivotal component in the U.S. oncology pharmacopeia, with numerous Abbreviated New Drug Applications (ANDAs) approved by the FDA, facilitating the availability of generic formulations. The FDA's Orange Book lists multiple approved ANDAs for irinotecan, underscoring its established presence in the market. The regulatory pathway for irinotecan involves stringent compliance with FDA guidelines, including adherence to Current Good Manufacturing Practices (cGMP) and successful demonstration of bioequivalence to the reference listed drug. Notably, there have been no recent import alerts or significant regulatory actions against Indian exporters of irinotecan, indicating consistent compliance with U.S. regulatory standards. Given the presence of 164 active Indian exporters, maintaining rigorous quality control and regulatory compliance is imperative to sustain and expand market share in the U.S.

In the European Union, irinotecan is subject to the European Medicines Agency's (EMA) centralized marketing authorization process or national procedures within member states. The EMA has conducted periodic safety update report single assessments (PSUSAs) for irinotecan, with notable assessments in March 2018 and March 2021, leading to variations in product information to enhance safety and efficacy profiles. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns closely with EMA standards, ensuring that irinotecan products meet stringent safety, efficacy, and quality requirements. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for manufacturers, necessitating regular inspections and certifications to ensure product quality and safety.

Irinotecan is included in the World Health Organization's (WHO) Model List of Essential Medicines, reflecting its critical role in cancer treatment. This inclusion underscores the global recognition of irinotecan's therapeutic importance and guides national health policies in ensuring its availability. Manufacturers are expected to comply with international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure consistent quality and efficacy across different markets.

In India, irinotecan is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, irinotecan is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure that domestic supply is not adversely affected by international demand.

The primary patents for irinotecan have expired, leading to a competitive generic market with multiple manufacturers producing the drug. This generic competition has contributed to the widespread availability and affordability of irinotecan globally.

In March 2025, the EMA granted orphan designation to irinotecan hydrochloride trihydrate for the treatment of small cell lung cancer, recognizing its potential benefit in addressing this rare condition. (ema.europa.eu) In December 2025, the FDA designated 7-ethyl-10-hydroxycamptothecin and irinotecan for the treatment of stomach cancer, including gastroesophageal junction cancer, as an orphan drug, highlighting its significance in treating these malignancies. Additionally, in February 2026, the FDA approved LONSURF (trifluridine/tipiracil) for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma, a regimen that includes irinotecan, reflecting ongoing advancements in combination therapies.

These developments underscore the dynamic regulatory landscape surrounding irinotecan, emphasizing the need for manufacturers and exporters to stay abreast of evolving standards and approvals to maintain compliance and market competitiveness.

Irinotecan, a critical chemotherapy agent, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, as reported by the U.S. Pharmacopeia in November 2025.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, the closure of the Strait of Hormuz disrupted the supply of naphtha, a vital feedstock for chemical production, leading to force majeure declarations and production cutbacks in Asia's chemical industry. Such disruptions highlight the fragility of supply chains dependent on specific regions for essential raw materials.

The export market for irinotecan from India is highly concentrated, with the top five exporters—Intas Pharmaceuticals Limited, Fresenius Kabi Oncology Limited, Eugia Pharma Specialities Limited, Sun Pharmaceutical Industries Limited, and Venus Remedies Limited—accounting for 85.6% of total exports. Notably, Intas Pharmaceuticals Limited alone holds a 35.8% share. This concentration poses a significant risk, as any operational or regulatory issues affecting these key suppliers could disrupt global supply chains.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, which are crucial for antibiotic production. While this initiative is a positive step, its impact on diversifying irinotecan's supply base remains to be seen.

The Strait of Hormuz and the Red Sea are vital maritime routes for global trade. In March 2026, escalating conflicts in the Middle East led to the effective shutdown of the Strait of Hormuz, disrupting the supply of raw materials to Asia's petrochemical industry. Simultaneously, major shipping lines suspended transits through the Red Sea due to heightened security threats. These disruptions have had cascading effects on the pharmaceutical supply chain, including potential delays in the delivery of critical medicines like irinotecan.

Furthermore, the U.S. Food and Drug Administration (FDA) has been monitoring supply chain vulnerabilities. In January 2025, the FDA highlighted the availability of antiviral medications and the challenges posed by supply chain disruptions. While specific shortage alerts for irinotecan have not been issued, the current geopolitical climate necessitates vigilant monitoring.

• Diversify Supplier Base: Engage with a broader range of API manufacturers to reduce reliance on a limited number of suppliers.

• Strengthen Domestic Production: Invest in local manufacturing capabilities for KSMs and APIs to decrease dependency on imports, particularly from geopolitically sensitive regions.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the origin and movement of raw materials and finished products, enabling quicker responses to disruptions.

• Develop Contingency Plans: Establish alternative logistics routes and maintain strategic stockpiles to mitigate the impact of shipping disruptions.

• Collaborate with Regulatory Bodies: Work closely with agencies like the FDA and EMA to stay informed about potential shortages and regulatory changes, ensuring compliance and proactive risk management.

RISK_LEVEL: HIGH